Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg, the company announced through an exchange filing.
Oxcarbazepine is used alone or with other medications to treat seizure disorders (epilepsy). The product will be manufactured at the group’s formulation manufacturing facility in Baddi, Himachal Pradesh (India).
Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg had annual sales of USD 105 mn in the United States (IQVIA MAT May 2023).
The group now has 374 approvals and has so far filed over 442 ANDAs since the commencement of the filing process in FY 2003-04.
Lakshya Sen Advances In Japan Masters
LGBTQ Fashion Influencer Faces Attacks In Delhi: Said, 'They Called Me A Disgrace To Sikhism'
Andhra Pradesh: 20-Year-Old Engineering Student Dies By Suicide In Hostel Room
Air India Express Mumbai-Varanasi Flight Receives Bomb Threat; Makes Emergency Landing, All 176 Passengers Evacuated
